SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Keryx Biopharmaceuticals, Inc. Merger

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors ("Board") of Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (NASDAQ CM: KERX) related to the Company's entry into an agreement to merge with Akebia Therapeutics, Inc. ("Akebia") (NASDAQ GM: AKBA) in a transaction announced on June 28, 2018 (the "Proposed Transaction").

On June 28, 2018, the Board caused Keryx to enter into an agreement and plan of merger (the "Merger Agreement") with Akebia. Pursuant to the terms of the Merger Agreement, shareholders of Keryx will receive 0.37433 common shares of Akebia for each share of Keryx they own.

On October 1, 2018, Akebia filed a Form S-4 Registration Statement ("Registration Statement") with the United States Securities and Exchange Commission ("SEC") in connection with the Proposed Transaction, which recommends that Keryx's shareholders vote in favor of the Proposed Transaction. Rigrodsky & Long, P.A. is investigating possible violations of law related to the Registration Statement, including whether the Registration Statement omits material information with respect to the Proposed Transaction.

If you own common stock of Keryx and purchased any shares before June 28, 2018, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/offices-contact.

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181002006059/en/